Anti CD38 monoclonal antibodies for multiple myeloma treatment.

Gozzetti, Alessandro; Ciofini, Sara; Simoncelli, Martina; Santoni, Adele; Pacelli, Paola; Raspadori, Donatella; Bocchia, Monica

Gozzetti, Alessandro; Ciofini, Sara; Simoncelli, Martina; Santoni, Adele; Pacelli, Paola; Raspadori, Donatella; Bocchia, Monica.

Afiliação

Gozzetti A; Department of Medical Science, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.
Ciofini S; Department of Medical Science, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.
Simoncelli M; Department of Medical Science, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.
Santoni A; Department of Medical Science, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.
Pacelli P; Department of Medical Science, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.
Raspadori D; Department of Medical Science, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.
Bocchia M; Department of Medical Science, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.

Hum Vaccin Immunother ; 18(5): 2052658, 2022 11 30.

Article em En | MEDLINE | ID: mdl-35404740

Assuntos

Antineoplásicos; Mieloma Múltiplo; ADP-Ribosil Ciclase 1/uso terapêutico; Anticorpos Monoclonais/farmacologia; Anticorpos Monoclonais/uso terapêutico; Antineoplásicos/uso terapêutico; Humanos; Mieloma Múltiplo/tratamento farmacológico

Palavras-chave

CD38; daratumumab; isatuximab; minimal residual disease; monoclonal antibodies; multiple myeloma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo / Antineoplásicos Limite: Humans Idioma: En Revista: Hum Vaccin Immunother Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google